Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement

Détails

Ressource 1Télécharger: 17416415.pdf (267.74 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_EDE42B00030B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
Périodique
Leukemia Research
Auteur⸱e⸱s
Knipp  S., Gattermann  N., Schapira  M., Kaferstein  H., Germing  U.
ISSN
0145-2126 (Print)
Statut éditorial
Publié
Date de publication
11/2007
Volume
31
Numéro
11
Pages
1585-7
Langue
anglais
Notes
Journal Article --- Old month value: Nov
Résumé
We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration. Since he had previously experienced ATRA syndrome, he received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF). Arsenic showed a peak CSF concentration of 0.008mg/l (0.11mumol/l) and a nadir of 0.002mg/l (0.027mumol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia.
Pubmed
Web of science
Création de la notice
25/01/2008 16:27
Dernière modification de la notice
20/08/2019 17:15
Données d'usage